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We hypothesized that soy isoﬂavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women
during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-
C, HDL-C, glucose, insulin, uric acid, C-reactive protein, ﬁbrinogen, and homocysteine. We collected data on 224 healthy
postmenopausal women at risk for osteoporosis (45.8–65y, median BMI 24.5) who consumed placebo or soy isoﬂavones (80
or 120mg/d) for 36 months and used longitudinal analysis to examine the contribution of isoﬂavone treatment, androidal fat
mass, other biologic factors, and dietary quality to cardiometabolic outcomes. Except for homocysteine, each cardiometabolic
outcome model was signiﬁcant (overall P-values from ≤.0001 to .0028). Androidal fat mass was typically the strongest covariate
in each model. Isoﬂavone treatment did not inﬂuence any of the outcomes. Thus, androidal fat mass, but not isoﬂavonetreatment,
is likely to alter the cardiometabolic proﬁle in healthy postmenopausal women.
1.Introduction
Menopause is associated with an increase in intra-abdominal
fat [1], which is considered a major risk factor of atheroscle-
rotic cardiovascular disease (CVD) [2]. However, whether
an increased risk of CVD in postmenopausal women is
due to altered body composition, changes in reproductive
hormones, or some other physiological process associated
with menopause has not been clearly established. It is
also uncertain as to what extent androidal fat mass may
inﬂuence CVD risk factors in healthy nonobese women.
The risk of chronic disease is perceived to be considerably
higher in obese compared to normal weight adults. However,
Gautier et al. [3] recently reported that the eﬀect of waist
circumference, reﬂecting androidal fat mass, in increasing
the risk for diabetes was more profound among men and
women with a normal body mass index (BMI) of less than
25kg/m2 than among those with above normal BMI. Thus,
it appears that eﬀorts to reduce abdominal fat accumulation
would be beneﬁcial regardless of BMI category.
This study was ancillary to the Soy Isoﬂavones for
Reducing Bone Loss (SIRBL) study, a randomized, double-
blind, placebo-controlled multicenter (Iowa State University
(ISU) and University of California at Davis (UCD)) clinical
trial funded by the National Institutes of Health (NIH) [4].
We examined contributors (androidal fat mass, duration of
menopause, isoﬂavone treatment, family history of CVD,
and dietary quality) to cardiometabolic risk in primarily
normal and overweight healthy postmenopausal women.
Cardiometabolic outcomes included circulating low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triacylglycerol, glucose, homeostatic
model assessment (HOMA) of insulin resistance, uric acid,
C-reactive protein (CRP), ﬁbrinogen, and homocysteine2 Cardiology Research and Practice
(Hcy). We hypothesized that consumption of soy isoﬂavones
in tablet form would attenuate the anticipated increase
in central fat (androidal) mass during the 36 months of
treatment, which in turn may favorably modify circulating
concentrations of cardiometabolic risk factors. We also
hypothesized that androidal fat mass, other biologic factors,
and dietary quality would inﬂuence these cardiometabolic
risk factors, but that androidal fat mass would predominate.
2.MaterialsandMethods
2.1. Overall Study Design. The parent study examined the
eﬀect of two doses (80 versus 120mg/day) of soy protein-
derived isoﬂavone versus placebo tablets for 36 months on
bone loss in healthy postmenopausal women (45 to 65
years of age) who were at risk for osteoporosis. The parent
study included power analysis on the primary outcome
(lumbar spine bone mineral density) in the methodology
and has been previously reported [4]. This ancillary project
focused on the relationship between body composition and
cardiometabolic risk factors. Many of these cardiometabolic
risk factors were tested throughout the study (LDL-C, HDL-
C, TAG, glucose, and uric acid) whereas some were only
tested through the 12 month time point (HOMA, CRP,
ﬁbrinogen, and Hcy). The respective Institutional Review
Boards (IRB) at ISU (ID no. 02-199) and at UCD (ID
no. 200210884-2) approved our study protocol, consent
form, and all participant-related materials. Approvals for the
dual-energy X-ray absorptiometry (DXA) procedures were
obtained from each institution’s IRB and State Department
of Public Health in Iowa and California. At prebaseline,
each participant received a detailed explanation of the study
verbally and in writing before signing an informed consent
form.
2.2. Participant Recruitment, Screening, and Selection. We
recruited (2003 to 2005) women throughout the state of
Iowa and in the greater Sacramento and Bay Area regions
in northern California primarily through direct mailing
lists, stories in local newspapers, and local/regional radio
advertisements. Responders (N = 5,255) were initially
screened via telephone to identify healthy women (without
diseases or conditions, not taking hormones or medications)
≤65 years who had undergone natural menopause (cessation
of menses 1 to 10 years), were not experiencing excessive
vasomotor symptoms, nonsmokers (not currently smoking
and who had not smoked in the past 6 months), and had a
BMI between 18.5 through 29.9 (except for 9 women from
UCD who did not meet the range of inclusion criterion: 8
women had BMI values that ranged from 30 to 32.7 and one
woman had a BMI of 17.8, but were enrolled because they
were deemed healthy).
The parent SIRBL project established the inclusion/excl-
usion criteria. We excluded vegans and high alcohol con-
sumers (>7servings/week), as well as those who were
diagnosed with chronic disease, had a ﬁrst-degree relative
with breast cancer, or who chronically used medication
(current: cholesterol-lowering and/or antihypertensive; past
3 months: antibiotics; past 6 months: estrogen/progestogen
creams, calcitonin; past 12 months: oral hormones/estrogen
or selective estrogen receptor modulators; ever: bisphospho-
nates).
Women who met the initial screening criteria (N = 677)
were invited to the clinic for further eligibility screening,
including BMD assessment using DXA. The SIRBL project
focused on disease prevention rather than treatment; thus,
women with BMD lumbar spine (L1-L4) and/or proximal
femur T-scores that were low (>1.5 SD below young adult
mean) or high (>1.0 SD above mean) or with evidence
of previous or existing spinal fractures were excluded.
Once each woman qualiﬁed based on BMD, fasting blood
was drawn for a clinical chemistry proﬁle. We excluded
women with evidence of diabetes mellitus (fasted glucose
≥6.93mmol/L (126mg/dl)), abnormal renal, liver (ele-
vated enzymes), and/or thyroid function, or elevated lipids
(LDL-cholesterol >4.10mmol/L (160mg/dl); triacylglycerol
>2.25mmol/L (200mg/dl)). Based upon our entry criteria,
we randomized 255 women to treatment in the parent trial.
We excluded 13 women at UCD from this analysis because
they did not meet the entry criteria (11 had thickened
endometrium, 1 had breast cancer, 1 could not provide
a baseline blood sample). We excluded an additional 19
women who did not have body composition data at either
12, 24, or 36 months because they dropped out of the
study, resulting in a sample size of 224 women based upon
androidal fat as our primary covariate of interest in this
ancillary project.
2.3. Randomization to Treatment and Tablet Formulation.
To meet the objectives of the parent project, participants
at each location (ISU, UCD) were stratiﬁed according to
baseline proximal femur BMD (high, medium, and low) [4]
based upon NHANES III database population values [5]a n d
randomly assigned to one of three treatment groups: placebo
control, 80mg isoﬂavones, or 120mg isoﬂavones. Tablets
were provided by The Archer Daniels Midland Co. (Decatur,
IL);tabletcompositionhasbeendescribedpreviously[4].An
independent researcher (Patricia Murphy) at ISU conﬁrmed
that the actual isoﬂavone doses (mean ± SD, mg/d) were
similar to those formulated and tested by Archer Daniels
Midland, respectively: control = 0 compared with 0.3 ± 0.4;
80mg = 89.5 ± 5.0 compared with 84.3 ± 4.5; 120mg =
124.0 ± 7.7 compared with 122.5 ± 3.4. Participants in each
group were instructed to take three compressed tablets/d. To
preserve the double-blind nature of the study, bottles did not
indicate treatment assignment.
2.4. Body Size and Composition Measures and Blood Sample
Measures. For this study, we used anthropometric and body
composition measurements that included weight, height,
whole body lean and fat mass, and androidal fat mass, as
well as fasting concentrations of lipids/lipoproteins, glucose,
and uric acid. These outcomes were assessed at baseline,
12, 24, and 36 months. In addition, circulating insulin,
HOMA (calculated as fasting glucose (mg/dL) × fasting
insulin (µU/mL)/405), CRP, ﬁbrinogen, Hcy, and red bloodCardiology Research and Practice 3
cell(RBC)folateconcentrationswereassessedatbaselineand
12 months.
Trained researchers obtained anthropometric measure-
ments according to standard protocols. Standing height was
taken twice (average value recorded) with a wall-mounted
stadiometer (Model S100; Ayrton Corp., Prior Lake, MN)
and weight was measured at ISU using a balance beam scale
(ABCO Health-o-Meter; Bridgeview, IL) and at UCD using
an electronic scale (Circuits and Systems Inc; E. Rockaway,
NY). Women wore hospital scrubs or shorts and a t-shirt,
and removed their shoes, belts, watches, and jewelry for
the duration of assessment. To ensure standardized data
collection, body composition measurements were obtained
by certiﬁed cross-trained DXA operators using matching
DXA instruments (Delphi W Hologic Inc; Bedford, MA) at
each site that were calibrated daily. To further ensure quality
control, one operator assessed overall composition from the
whole body DXA scans for both sites. Regional adiposity
analysis was performed by one analyzer (LR) who sectioned
each whole body DXA scan into waist, hip, and thigh
regions based on bone landmarks [6] using special software
(Discovery Version 12.3:7). The waist region included the
ﬁrst lumbar through the fourth lumbar vertebrae. The
hip region began below the fourth lumbar vertebrae and
extended to the tip of the greater trochanter of the femur.
Androidal fat mass (kg) for each participant was the sum of
waist and hip fat mass.
Phlebotomists collected fasted (9h) blood samples
between 7:00 and 8:00 am. We separated serum (allowed
to clot for 30min prior to centrifugation) and plasma
from whole blood and centrifuged samples for 15 minutes
(4◦C) at 1000×g, storing aliquots at −80◦C until analyses.
Certiﬁed clinical laboratories (LabCorp; Kansas City, KS for
ISU and UCD Medical Center; Sacramento, CA for UCD)
performed a chemistry panel (including serum glucose,
lipid proﬁle, and uric acid) on each participant at each
time point. We measured the remaining analytes (serum
insulin, serum CRP, plasma ﬁbrinogen, plasma Hcy, and
RBC folate) for each participant in batch from ISU and
UCD samples at baseline and 12 months in duplicate at
ISU. We used suﬃcient in-house sera/plasma as quality-
control samples (frozen at −80◦C) to run with each kit
to calculate interassay coeﬃcient of variation (CV); we
used duplicate samples to calculate intraassay CV. The low-
to-normal and normal-to-high controls for each kit were
well within the acceptable ranges. Serum insulin (µU/mL)
concentration was determined with a radioimmunoassay
kit (Linco Research, St Charles, MO, USA) using a Cobra
II series autogamma counting system (Packard Instrument
Company; Meriden, CT, USA). The intra- and interassay
CV for insulin were 3.0% and 4.0%, respectively. Serum
CRP (mg/L) concentration was determined with a high-
sensitivity sandwich enzyme-linked immunosorbent assay
kit (ALPCO Diagnostics; Salem, NH) and plasma (hep-
arinized)ﬁbrinogen(mg/mL)concentrationwasdetermined
with a sandwich enzyme-linked immunosorbent assay kit
(AssayPro; St. Charles, MO) using a microtiter plate reader
(ELx808; Bio-Tek Instruments, Inc., Winooski, VT). The
intra-assayCVsforCRPandﬁbrinogenwere3.7%and2.7%,
respectively; the interassay CVs for CRP and ﬁbrinogen
were 6.0% and 2.3%, respectively. Total Hcy (µmol/L)
concentration was determined using a high-performance
liquid chromatography (HPLC) method adapted from Araki
and Sako [7] and Ubbink et al. [8]. The total Hcy in
plasma consists of free Hcy (i.e., reduced plus oxidized Hcy
in the nonprotein fraction of plasma) and protein-bound
Hcy [9]. N-Acetylcysteine (1mM) was added as an internal
standard to the plasma samples prior to derivatization.
The ﬂuorescence intensities were measured with excitation
at 385nm and emission at 515nm, using a JASCO FP-
1520 ﬂuorescence detector. Further assay details have been
previously published [9]. The intra- and interassay CV for
plasma Hcy were 3.8% and 6.3%, respectively. Intracellular
(RBC) folate (ng/mL) was measured using a radioactive
immunoassay kit (MP Biomedicals; Irvine, CA). Because
four hematocrit values were missing, RBC folate could not
be calculated for these four samples. In addition, three
baselinesampleswereincorrectlyprocessed;thus,RBCfolate
values have been presented for 217 women. The intra-
and interassay CV for RBC folate were 3.2% and 11.8%,
respectively.
2.5. Interviewer-Administered Questionnaires. During the
enrollment phase, trained interviewers administered three
questionnaires to participants: a health and medical history
[10–12], a reproductive history [13], and a nutrition history
[10, 11]. We also gathered data on prescription and over-
the-counter medications at each time point, as well as
previous and/or current use of herbal therapies or dietary
supplements (which they were asked to discontinue prior
to baseline testing). We assessed dietary intake at each time
point using a semiquantitative food frequency questionnaire
from Block Dietary Data Systems (Berkeley, CA). A Healthy
Eating Index (HEI) score, with higher scores representing
greater adherence to federal dietary guidelines, was calcu-
lated for each participant based on this questionnaire and
included in the statistical analyses as a covariate.
2.6. Statistical Analysis. We performed statistical analyses
using version 2.10.1 of the R software, including version
3.1.96 of the nlme package software and considered results
statistically signiﬁcant (two sided) at P ≤ .05. Our 3-year
longitudinal analyses of LDL-C, HDL-C, triacylglycerol, and
glucose included women with complete data at all time
points, baseline through 36 months. Our 1-year longitudinal
analyses of ﬁbrinogen, insulin, HOMA, Hcy, and CRP
included women with complete data at baseline and 12
months. We reported descriptive statistics for 224 women
using median and interquartile range. We constructed lon-
gitudinal models to identify signiﬁcant contributors to each
cardiometabolic risk factor (LDL-C, HDL-C, triacylglycerol,
uric acid, glucose, insulin, HOMA, CRP, ﬁbrinogen, and
Hcy). Each ﬁnal longitudinal model included these obliga-
toryvariables:treatment(controlversuscombinedtreatment
with 80mg or 120mg of isoﬂavones or, in other words,
no treatment versus treatment), time point (baseline versus
12, 24, or 36 months), treatment by time point interaction,4 Cardiology Research and Practice
and site (ISU versus UCD), as well as potential covariates
that included androidal fat mass (kg) adjusted for height,
time since last menstrual period (TLMP) (yr) (calculated for
each woman: baseline test date—date of her last menstrual
period),familyhistoryofCVDcodedasacategoricalvariable
(none versus positive or none versus unknown), and HEI
score. Additionally, the insulin model included glucose as
a covariate, and the Hcy model included RBC folate as a
covariate. Independent variables in modeling the outcomes
of interest included those variables that were biologically
plausible.Preliminarymodelsalsoincludeddietaryfatintake
(determinedusingtheBlockFoodFrequencyQuestionnaire)
and physical activity (determined using the Paﬀenbarger
physical activity recall [14]), but those variables did not
emerge as remotely signiﬁcant contributors to any of the
cardiometabolic risk factors and thus were not included in
the ﬁnal models.
Separate height adjustments of fat and fat-free mass
have been suggested for children by Wells and Cole [15];
accordingly, we found a signiﬁcant impact of height on
androidal fat mass among the participants in our study
based on a log-log regression analysis (parameter estimate
0.8286, P = .0058). This suggested the use of height-
adjusted androidal fat mass (androidal fat mass (g)/height
(cm)) (exponent of 0.8286 for height changed to 1 for ease
of interpretation). In other words, we adjusted androidal fat
mass for height because taller women typically had greater
waist circumferences due to their larger frame size and
thus appeared to be at higher risk for CVD compared with
shorter women, whereas this is not necessarily the case.
We performed log transformation of variables with skewed
distributions: triacylglycerol, HOMA, CRP, Hcy, and RBC
folate.
Restricted maximum likelihood (REML) estimation was
used to obtain estimates of variances and correlations
between repeated measures. Model selection was guided by
a stepwise backwards selection based on model diagnostics,
suchasAkaike’sinformationcriterionandBayesinformation
criterion. An overall model ﬁt was obtained based on a likeli-
hood ratio test of the (maximum likelihood ﬁtted) model at
hand and the more parsimonious model of only obligatory
covariates. Signiﬁcance indicates a failure to accept the null
hypothesis of covariates contributing to the model in a
random fashion. More speciﬁcally, signiﬁcance indicates that
the full model with all of the variables included explains a
greater proportion of the variability in the outcome than the
parsimonious model.
3. Results
3.1. Cardiometabolic Risk Factors Assessed during a 36-
Month Period. Baseline values for body composition and
cardiometabolic outcomes are summarized in Table 1.B o d y
composition measurements, including androidal fat mass,
did not change signiﬁcantly during the course of the study.
The isoﬂavone treatment did not have an eﬀect on any of
the body composition outcomes. Treatment compliance was
veriﬁedusingurinaryisoﬂavoneconcentrations.Compliance
was excellent [4]. The results of longitudinal analysis showed
that each cardiometabolic outcome model was highly signif-
icant, with overall P-values ≤ .0001 for all but the LDL-C
model (P = .002). Signiﬁcant covariates for each analyte
are shown in Table 2. Androidal fat mass and site (ISU
versus UCD) were consistent predictors of all analytes (36
month data) assessed, including lipids/lipoproteins, glucose,
and uric acid. In general, androidal fat mass was typically
the strongest covariate (positive) in each model (except the
modelwithHDL-Castheoutcome,whereitwassigniﬁcantly
and negatively associated). Time point also emerged as a
signiﬁcant covariate in the HDL-C and glucose models,
indicating that the median concentrations of these analytes
increased with time; however, the analyte concentrations
at subsequent time points were not signiﬁcantly diﬀerent
compared to baseline. The median glucose concentration
was 85mg/dL at baseline and 88mg/dL at 36 months. The
median HDL-C concentration was 64mg/dL at baseline
and 65mg/dL at 36 months. Family history of CVD had
a signiﬁcant association with glucose: women who were
unaware of their family history (“do not know,” n = 9),
taking into account key factors in the model, had on average
a 6.8mg/dL higher glucose concentration compared with
women who indicated that they had a positive family history.
Isoﬂavone treatment, TLMP, or HEI did not inﬂuence any of
the 36 month analytes.
3.2. Cardiometabolic Risk Factors Assessed during a 12-
Month Period. Similar to the 36 month outcomes, each
12 month outcome model was highly signiﬁcant (overall
model P-values ≤.0001), except for Hcy (P = .23, data
not shown). Androidal fat mass was positively associated
with each outcome (Table 3) and was the strongest covariate
(positive) in each model. The parameter estimate for site
was negative, indicating that the women from UCD had
lower values than the women at ISU. In addition, TLMP
(P = .0020) and TLMP-by-site interaction (P = .0021)
contributed signiﬁcantly, and a positive family history of
CVD contributed marginally (P = .070) to ﬁbrinogen
concentration. As TLMP increased, the diﬀerence in ﬁb-
rinogen concentration between the sites decreased. Glucose
and time were signiﬁcant covariates in the insulin model.
As expected, a higher glucose concentration was associated
with a higher insulin concentration. The unadjusted mean
insulin concentration was signiﬁcantly greater (2.86µU/mL;
P ≤ .0001) at 12 months compared with baseline. Isoﬂavone
treatment or HEI did not emerge as signiﬁcant predictors in
any of the 12 month models.
4. Discussion
The main objective of this study was to identify sig-
niﬁcant contributors to cardiometabolic risk in primarily
normal and overweight (BMI<30) healthy postmenopausal
women. In agreement with our hypothesis, androidal fat
mass was the strongest and most consistent predictor of
all cardiometabolic outcomes (except for Hcy) examined
in this study. Our participants, as a group, showed noCardiology Research and Practice 5
Table 1: Characteristics of participants at baselinea.
Quartile
Nb Median First Third Min Max
Age (y) 224 54.33 52.06 56.79 45.84 65.04
TLMPc (y) 224 2.76 1.76 5.02 0.79 10.02
Family History of CVD (n) 224
No 88
Yes 127
Don’t know 9
Weight (kg) 224 66.35 59.98 73.70 43.70 93.10
BMI (kg/m2) 224 24.46 22.33 27.03 17.84 31.66
Whole body fat massd (%) 224 34.4 30.45 38.36 18.12 45.95
Androidal fat massd (kg) 224 5.31 4.19 7.12 1.12 10.7
Serum total cholesterol (mg/dL) 224 206.5 189 226.2 142 297
Serum LDL-C (mg/dL) 224 127.5 109 141.2 62 192
Serum HDL-C (mg/dL) 224 64 55.75 76 30 111
Serum triacylglycerol (mg/dL) 224 76 59 98.25 18 290
Serum C-reactive protein (mg/L) 218 1.022 0.453 2.089 0.013 29.860
Plasma ﬁbrinogen (mg/mL) 218 3.353 2.657 4.311 0.914 6.854
Plasma total homocysteine (µmol/L) 218 7.296 6.318 7.677 4.224 17.64
RBC folate (ng/mL) 217 10.45 8.896 12.82 4.595 40.13
Blood glucose (mg/dL) 224 85 80.75 90 57 117
Serum insulin (µU/mL) 218 11.39 8.437 13.96 0.104 36.14
HOMAe 218 2.362 1.694 3.006 0.022 9.458
Serum uric acid (mg/dL) 224 4.15 3.5 4.8 1.3 9
Systolic BP (mm/Hg) 224 119.5 112.8 132 93 170
Diastolic BP (mm/Hg) 224 74.5 68 80 49 111
Resting heart rate (bpm) 224 68 63 74 44 99
Healthy Eating Index score 224 67 56 76 37 95
aBaseline data are reported for the entire sample. Treatment groups did not diﬀer signiﬁcantly in any of the outcomes at baseline.
bThe number of observations available at baseline
cTime since last menstrual period
dAssessed using dual-energy X-ray absorptiometery (DXA)
eHomeostatic model of insulin resistance
signiﬁcant changes in body composition measurements,
including androidal fat mass, during the course of the
study. It should be noted, however, that the women were
instructed to maintain their weight throughout the course
of the study by following their usual diet and physical
activity patterns, and hence, we did not expect to document
overall or androidal fat mass change from baseline to 36
months. Similarly, with the exception of insulin, none of the
cardiometabolic risk factors changed signiﬁcantly between
baseline and the time of ﬁnal assessment (either 12mo or
36mo). Nevertheless, strong associations between androidal
fat and cardiometabolic risk factors suggested that even a
small increase in androidal fat mass may have considerable
health consequences. Indeed, Biggs et al. [16] reported that
the incidence of type 2 diabetes was 70% higher (a hazard
ratio of 1.7) in adults 65 years of age and older who gained
at least 10cm in waist circumference over several years
compared with those who remained within 2cm of their
baseline waist circumference. Although the Biggs’s study did
not speciﬁcally target postmenopausal women, it provided
some insight into the magnitude of the impact of central
adiposity on the incidence of type 2 diabetes.
Certain factors such as duration of menopause,
isoﬂavone treatment, and diet quality that are recognized
in the literature as inﬂuential with respect to cardiovascular
health did not emerge as signiﬁcant predictors of the
cardiometabolic outcomes examined in this study. Some
of our ﬁndings are consistent with previous reports. For
instance, DeNino et al. [17] found that the relationship
between age and blood lipids in nonobese women was
abolished after controlling for visceral fat. Similarly, in
our study, TLMP did not emerge in any model (except
for ﬁbrinogen) as a signiﬁcant covariate, because time
point took precedence over TLMP. Results also suggested
that androidal fat mass in combination with other factors
predominated in these cardiometabolic risk models. On
the other hand, our ﬁndings for isoﬂavone treatment
and dietary quality conﬂict with some of the previously
published reports. The lowering eﬀect of soy protein rich
in isoﬂavones on blood lipids/lipoproteins, albeit modest6 Cardiology Research and Practice
Table 2: Longitudinal analysis: covariates associated with each outcome variablea assessed from baseline through 36 months (N = 224).
Outcome variable Independent
variable
Likelihood ratiob Parameter estimate Std. error t value Pr(>t)
LDL-C Androidal fat mass 8.93 0.274 0.092 2.99 0.0029
Site 16.102 2.649 6.08 ≤0.0001
HDL-C Androidal fat mass 41.13 −0.337 0.052 −6.51 ≤0.0001
Site −6.819 1.941 −3.51 0.0005
Time point 12 1.479 1.065 1.39 0.17
Time point 24 2.106 1.066 1.98 0.049
Time point 36 3.607 1.066 3.38 0.0008
Triacylglycerol Androidal fat mass 73.19 0.006 0.001 8.79 ≤0.0001
Site −0.045 0.019 −2.37 0.019
Glucose Androidal fat mass 36.13 0.165 0.031 5.28 0.0032
Site −2.310 0.894 −2.59 0.010
Time point 12 2.802 1.015 2.76 0.0059
Time point 36 3.599 1.015 3.55 0.0004
FamHx “don’t
know”
6.868 2.303 2.98 0.0032
Uric Acid Androidal fat mass 49.30 0.027 0.004 7.19 ≤0.0001
Site 0.427 0.112 3.81 0.0002
aEach ﬁnal longitudinal model included obligatory variables: treatment (control versus combined treatment with 80mg or 120mg of isoﬂavones), time point
(baseline versus 12, 24, or 36 months), treatment by time point interaction, and site (ISU versus UCD), as well as potential covariates that included androidal
fat mass (kg) adjusted for height, time since last menstrual period (TLMP), family history of CVD (Fam Hx) coded as a categorical variable (none versus
positive or none versus unknown), and Healthy Eating Index (HEI) score. This table shows only those covariates that were signiﬁcant (P ≤ .05) for each
o u t c o m ev a r i a b l eo rh a dat e n d e n c y( P ≤ .10) to be signiﬁcant.
bThelikelihoodratioforeachmodelrepresentstheratioofamodelthatincludesonlyobligatoryvariablescomparedtotheﬁnalmodelthatincludesobligatory
variables and covariates. The overall P value for each model was ≤.0001, except the LDL model had a P value = .0028.
(≤6% reduction), has been documented [18, 19]. The eﬀect
is more profound in hypercholesterolemic individuals and in
males. Similarly, the eﬀect of diet quality on CVD outcomes
is well known: a healthier diet (high in ﬁber and low in
fat and sodium) is associated with a lower risk of CVD
[20, 21]. We included both a HEI score as a measure of diet
quality and isoﬂavone treatment in our analysis. None of
the models retained either covariate. The lack of association
between HEI and cardiometabolic outcomes in our study
could be in part explained by a majority of women who
had relatively healthy diets (median HEI of 67 out of 100).
Very few studies have examined the association between
HEI and cardiometabolic outcomes with mixed results.
For instance, Kant and Graubard [22] reported that HEI
emerged as a negative predictor of serum Hcy, CRP and
plasma glucose (P<. 05), whereas Fung and colleagues [23]
did not ﬁnd an association between HEI and CRP. In a recent
study of 125 multiethnic overweight and obese women in
early postpartum, the HEI scores were negatively associated
with LDL-C and total cholesterol and positively related to
HDL-C after adjustment for energy intake, body weight, and
lactation status [24].
Based on the results of our study, HEI does not appear
to be a predictor of cardiometabolic risk factors. On the
other hand, the eﬀects of dietary factors as well as isoﬂavone
treatment on cardiometabolic outcomes may be mediated
by androidal fat mass. We previously reported that soy
isoﬂavone treatment for 12 months did not exert an eﬀect
on body composition, including androidal fat, in our sample
of women [25]. With respect to diet, Fox et al. [26]
determined that premenopausal women who participated in
a 24 week diet and/or exercise program showed reductions
in weight (∼7kg) and total percentage body fat (although
it remained greater than 35% for all groups), but no
signiﬁcant improvements in blood lipids, glucose, or insulin
concentrations. Further analysis revealed a lack of change
in the waist-to-hip ratio, which in turn indicated that body
fat distribution was not inﬂuenced by the intervention. To
summarize, dietary interventions that are not suﬃciently
potent to reduce androidal fat mass are not likely to produce
changes in cardiometabolic outcomes.
In addition to androidal fat mass, the other most com-
monindependentpredictorsofcardiometabolicoutcomesin
our study included time and site. Although concentrations
of HDL-C and glucose did not change signiﬁcantly during
the study, both analytes showed an upward trend from
baseline to 36mo. The eﬀect of time could be related to
biological and/or behavioral factors that were not included
in our models. In fact, TLMP was no longer signiﬁcant when
time was included, indicating that time was more important
than TLMP. The site variable also emerged as a signiﬁcant
covariate in all models: compared with women at ISU,Cardiology Research and Practice 7
Table 3: Multivariate linear regression: covariates associated with each outcome variablea assessed from baseline through 12 months.
Outcome variableb Independent
variable
Likelihood ratioc Parameter estimate Std. error t value Pr(>t)
CRP Androidal fat mass 90.69 0.052 0.005 24.50 ≤0.0001
Site −0.236 0.121 10.79 0.072
Fibrinogen Androidal fat mass 31.63 0.012 0.004 4.32 ≤0.0001
Site −1.469 0.227 −6.48 ≤0.0001
TLMP −0.118 0.038 −3.13 0.0020
TLMP × Site 0.159 0.051 3.12 0.0021
Positive Fam Hist 0.204 0.112 1.82 0.070
Insulin Androidal fat mass 51.16 0.143 0.024 5.95 ≤0.0001
Site −4.516 0.588 −7.68 ≤0.0001
Time point 12 2.013 0.650 3.1 0.0022
Glucose 0.095 0.028 3.4 0.0008
HOMA Androidal fat mass 43.73 0.012 0.002 6.88 ≤0.0001
Site −0.312 0.039 −7.92 ≤0.0001
Time point 12 0.011 0.004 3.44 0.0007
aThe number of observations included in the analysis varied depending on the outcome: N = 217 for CRP and Hcy, N = 218 for ﬁbrinogen, insulin, and
HOMA. The Hcy model was not statistically signiﬁcant and thus not shown in this table.
bEach ﬁnal longitudinal model included these obligatory variables: treatment (control versus combined treatment with 80mg or 120mg of isoﬂavones), time
point (baseline versus 12, 24, or 36 months), treatment by time point interaction, and site (ISU versus UCD), as well as potential covariates that included
androidal fat mass (kg) adjusted for height, time since last menstrual period (TLMP), family history of CVD (FamHx) coded as a categorical variable (none
versus positive or none versus unknown), and Healthy Eating Index (HEI) score. The ﬁbrinogen model included TLMP by site interaction. The insulin model
(but not other models) included glucose as a covariate. This table shows only those covariates that were signiﬁcant (P ≤ .05) for each outcome variable or had
at e n d e n c y( P ≤ .10) to be signiﬁcant.
cThelikelihoodratioforeachmodelrepresentstheratioofamodelthatincludesonlyobligatoryvariablescomparedtotheﬁnalmodelthatincludesobligatory
variables and covariates. The overall P-value for each model was ≤.0001.
women at UCD had lower concentrations of triacylglycerol,
HDL-C, glucose, insulin, HOMA, CRP, and ﬁbrinogen and
higher concentrations of LDL-C and uric acid. The site eﬀect
may be in part explained by baseline characteristics: ISU
women were slightly (albeit not signiﬁcantly) heavier and
youngercomparedwithUCDwomen.Itisalsoquitepossible
that the site eﬀect was due to some inherent diﬀerences
between the two geographic locations. We did not document
a relationship between androidal fat mass, as well as other
factors, and Hcy likely because the women in our study were
well below the clinical cut-oﬀ of 15, and Hcy values did not
indicate great variability.
Some of the strengths of our study were that we
followed a relatively large number of women and monitored
longitudinal changes (baseline to 12 or 36mo) in car-
diometabolicriskfactors.Limitationswerethatthesewomen
were free-living (both a strength and limitation), lacked
ethnic diversity, and underwent infrequent measurements
(yearly). Women in this study were mainly nonobese based
upon the BMI deﬁnition. However, BMI does not adequately
reﬂect body composition. Thus, some of our women may
have been identiﬁed as obese using other criteria, such as
percentage body fat (35–40% = overweight, >40% = obese
[27]). In conclusion, although cardiometabolic outcomes
examined in this study were not aﬀected by isoﬂavone
treatment, each outcome (except for Hcy) had a strong, sig-
niﬁcantassociationwithandroidalfatmass.Thus,evensmall
changesinandroidalfatarelikelytoalterthecardiometabolic
proﬁle in healthy postmenopausal women.
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